Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-07257876 |
| Synonyms | |
| Therapy Description |
PF-07257876 is a bispecific antibody that targets CD47 and PD-L1 (CD274), which may lead to increased phagocytosis and enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing CD47 and PD-L1 (CD274) (NCI Thesaurus). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-07257876 | PF 07257876|PF07257876 | CD47 Antibody 31 PD-L1 Inhibitor 15 | PF-07257876 is a bispecific antibody that targets CD47 and PD-L1 (CD274), which may lead to increased phagocytosis and enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing CD47 and PD-L1 (CD274) (NCI Thesaurus). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | Advanced Solid Tumor | predicted - sensitive | PF-07257876 | Phase I | Actionable | In a Phase I trial, PF-07257876 treatment was well tolerated in patients with PD-L1 (CD274)-positive advanced solid tumors and resulted in an objective response rate of 5.6% (1/18, 1 partial response in a patient with head and neck squamous cell carcinoma) (J Clin Oncol 41, 2023 (suppl 16; abstr 2529); NCT04881045). | detail... |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04881045 | Phase I | PF-07257876 | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | Completed | USA | ESP | 0 |
CKB BOOST